Two Onc Docs

Dive into treatment options for localized breast cancer, from radiation to systemic therapies. Explore criteria for radiation post-mastectomy and personalized systemic therapy choices. Learn about chemotherapy regimens based on receptor status and side effects of treatments. Discover tailored treatment strategies based on tumor features, receptor status, and patient preferences, including neoadjuvant chemotherapy for inflammatory breast cancer.

Breast Cancer Awareness Month is here! Learn about genetic and non-genetic risk factors for breast cancer, the importance of breast screenings, differences between DCIS and LCIS, treatment options like mastectomy and lumpectomy, side effects of hormone therapy, and surgical options for invasive breast cancer.

Dive into the world of Immune Thrombocytopenia (ITP) as the hosts explore its causes and idiopathic cases. Uncover the prevalence of this acquired condition and the importance of accurate diagnosis with low platelet counts. Learn about comprehensive management strategies including conservative treatments for kids and intensive options for adults. Key insights on first-line therapies like steroids and IVIG are also discussed, alongside the significance of timely management during bleeding episodes.

This podcast focuses on diffuse large B-cell lymphoma (DLBCL), covering topics such as diagnostic classification, subtypes and molecular markers, necessary tests and evaluations, staging and treatment options, and different treatment regimens for refractory DLBCL. It emphasizes the importance of excisional lymph node biopsy for accurate diagnosis, highlights prognostic factors and high-risk patient considerations, and discusses the use of R-CHOP chemotherapy, radiation, and CAR T therapy. The recommended follow-up protocol for cured patients is also covered.

Exploring the evolving treatment options for metastatic non-small cell lung cancer, including traditional chemotherapy, immunotherapy, and targeted agents. Discussing the significance of targeted medications like EGFR, ALK, and ROS1 inhibitors. Emphasizing the importance of genetic mutation-based sequencing and tailored drug regimens based on PDL1 status.

This podcast delves into the complexities of localized non-small cell lung cancer, covering staging criteria, treatment options, including surgery, chemo, radiation, and immunotherapy. The discussion also highlights the impact of the PACIFIC trial on treatment standards and explores emerging therapies like egf targeting and immunotherapy.

Important details on risk factors, diagnosis, staging, and treatment options for uterine cancer, including less common subtypes. Risk factors include obesity and hormone replacement therapy. Treatment options include surgery, hormone therapy, radiation, and chemotherapy. Uterine sarcomas have different treatment regimens, with the addition of trastuzumab for HER2 positive tumors.

Delve into the fascinating world of hemophilia with insights into the key differences between hemophilia A and B, including their genetic factors. Learn about diagnostic methods, severity classifications, and the importance of family history. Discover effective treatment strategies, focusing on prophylactic factor replacement therapy and its protocols. Explore the challenges posed by inhibitors in treatment and the autoimmune origins of acquired factor deficiencies, particularly in the elderly. Get informed on managing bleeding events and enhancing patient care.

This podcast discusses the risk factors, diagnosis, staging, and treatments for ovarian cancer. It highlights the importance of early detection, germline mutation testing, and the use of carbotaxil as a preferred chemotherapy drug. The podcast also explores treatment options for recurrent disease and different histological types of ovarian cancer.

This week’s episode will be focusing on Hodgkin's Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into all the important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.